Clinical utility of the PLAC® Activity Test

The PLAC® Test for Lp-PLA2 Activity (PLAC Activity) improves primary prevention of CHD events

The PLAC Activity Test identifies risk in patients independent of other risk factors

The PLAC Activity Test is easy to use and is supported by robust clinical study data

Lp-PLA2 testing is well studied and published in peer-reviewed scientific literature and is recognized in the American Heart Association Guidelines, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice, and European Guidelines on CVD Prevention in Clinical Practices. See guidelines and recommendations.

Please also visit our Clinical Knowledge Portal to discover a suite of reference tools, clinical support materials, and expert perspectives on CHD risk, Lp-PLA2, and PLAC Activity testing.

References: 1. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.Arterioscler Thromb Vasc Biol. 2006;26(11):2523-2529. 2. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111-117.e2. 3. Data on file. Diadexus, Inc. 4. PLAC® Test for Lp-PLA2 Activity [package insert]. South San Francisco, CA: Diadexus, Inc; 2015. 5. Thompson A, Gao P, Orfei L, et al; Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536-1544.